Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069016 | 0.90 | F2 (0.41) | MMP2ANPEPF2 | |
| SCHEMBL17464831 | 0.82 | HSD17B10 (0.41) | — | |
| SCHEMBL17464830 | 0.76 | MMP2 (0.53) | MMP2ANPEP | |
| SCHEMBL2771429 | 0.76 | MMP2 (0.53) | MMP2ANPEP | |
| SCHEMBL4721124 | 0.75 | SMN1; SMN2 (0.36) | MMP2ANPEPF2 | |
| SCHEMBL2303013 | 0.71 | RAB9A (0.41) | NOS3NOS2 | |
| SCHEMBL5702257 | 0.69 | ATM (0.50) | F2 | |
| SCHEMBL5702101 | 0.69 | ATM (0.50) | F2 | |
| SCHEMBL14441518 | 0.69 | ATM (0.50) | F2 | |
| SCHEMBL17069019 | 0.67 | F2 (0.41) | F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403813-B2 | Azetidine amide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20160024064-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024064-A1 | AZETIDINE AMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY2R | MMP2 3553/4885ANPEP 756/4885NOS3 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.